Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova for CV risk reduction in hypertriglyceridemia with low HDL-C
CTR20160171Phase 3Completed
- Sponsor
- Fisher Clinical Services
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia, dyslipidemia, cardiac morbidity, sponsored by Fisher Clinical Services. Started Mar 2016; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemiadyslipidemiacardiac morbidity
Beyond the preview
Go deeper on CTR20160171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160171.